Chemicals and reagents
Bovine Albumin (fraction V, purity 96–99%) and glutaraldehyde were obtained from Sigma (Steinheim, Germany). Docetaxel was from Cipla (Mumbai, India). For in-vitro cytotoxicity test, amniotic epithelial cells were obtained from elective Cesarean. For cellular uptake, HeLa Cells were obtained from Pasteur Institute. RPMI 1640 and Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 and fetal bovine serum (FBS) were obtained from GIBCO Invitrogen Corporation. 3-(4,5 Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), dimethylsulfoxide (DMSO) and epidermal growth factor (EGF) were from Sigma.
Preparation of albumin nanoparticles
Albumin nanoparticles crosslinked with glutaraldehyde were prepared by desolvation technique as described previously (
15). Briefly, 150 mg albumin was dissolved in 2.0 mL of 10 mM NaCl solution, titrated to pH 7-10. The solution was then transformed into nanoparticles by continuous addition of 8.0 mL of the desolvating agent ethanol under stirring (500 rpm) at room temperature. The addition of ethanol was performed by a syringe pump (Model SP-500, JMS Co., LTD; Japan) which enabled nanoparticles preparation at flow rate 1 mL/min of ethanol. After the desolvation process, 8% glutaraldehyde in water was added to induce particle crosslinking (1.175 μL/mg serum albumin). The crosslinking process was performed under stirring of the suspension over a time period of 24 hours. The same preparation technique was used in all other groups, before crosslinking by glutaraldehyde. One group was placed in the UV chamber under UV light (wavelength 254 nm) for 30 minutes. The distance between the light source and the sample was 15 cm (
19,
20). The other group was treated with 6 mM glucose (D-glucose, 99.5% anhydrous, Sigma Chemical Co., St. Louis, MO). The same protocol was applied for the third group (UV+ glucose) in which the addition of glucose was followed by immediate exposure to UV source for the same period of time and same intensity and distance, as mentioned above.
Determination of particle size and zeta potential
Average particle size and zeta potential were measured by photon correlation spectroscopy (PCS) and micro electrophoresis using a Malvern zetasizer 3000 HSA (Malvern Instruments Ltd., Malvern, UK). The samples were diluted 1:400 with purified water and measured at a temperature of 25 °C and a scattering angle of 90°. Scanning electron microscope showed the shape of albumin nanoparticles after lyophilization.
Purification of nanoparticles
The resulting nanoparticles were purified by five cycles of differential centrifugation (15,000 × g, 10 min) and re-dispersion of the pellet to the original volume in 10 mM NaCl at pH 8.2. Each re-dispersion step was performed in an ultrasonication bath (Power Sonic 410, Maihan LabTech, Korea) over 5 min.
Characterization of nanoparticles
FT-IR spectra were recorded on a 102 MB BOMEM apparatus. Samples for FT-IR measurements were prepared by dissolving them in 1.5 wt% aqueous solution containing phosphate buffer 0.1 M NaCl (pH 7.2). IR spectra were recorded on hydrated film, using AgBr windows with a resolution of 2-4 cm-1 and 100-500 scans.
Cellular uptake of albumin nanoparticles
HeLa cancer cells were cultured as described previously (
21). In brief, the cancer cells were seeded in 24-well-plates at a density of 2×10
4 cells per well and cultured at 37 °C and 5% CO
2 in RPMI 1640 (Biochrom, Berlin, Germany) supplemented with antibiotics (100 U/mL penicillin and 100 µ/mL streptomycin; Gibco, Berlin, Germany) and fetal bovine serum (FBS), for about 2 days till the cells reached 70% confluence. Then the cells were incubated with prepared nanoparticles conjugated with fluorescent for 4 hours at 37 °C and 5% CO
2. For imaging, HeLa cells were gently rinsed with DMEM/FBS twice and subsequently fixed in formaldehyde 4% for 5 minutes. The photos were taken by invert fluorescent microscope.
MTT assay
Human amniotic epithelial (AE) cells were prepared using fresh human placenta after elective Cesarean, as described previously (
22). The AE cells were seeded at density of 5×10
4 per well in gelatin-coated 24-well plate and incubated overnight in incubator (37 °C, 5% CO
2) in DMEM/F12 supplemented with 10% FBS. The AE cells were incubated with 250 µL suspension of the nanoparticles overnight. Then the cells were washed using phosphate buffered saline (PBS) at pH 7.4. The cells without treatment were used as control group. For cytotoxicity assay, 250 µL of MTT solution (5 mg/mL) was added to each well and the plates were incubated for 4 h. The MTT formazan crystals were then dissolved with 1 mL DMSO at room temperature. The optical density (OD) was measured at 570 nm with a spectrophotometer (CE7500, Cecil, UK). The blank well (containing only medium) was used for zero adjustment. The viable rate was calculated by the following equation:
Viable rate = (ODtreated/ODcontrol )× 100%
ODcontrol was obtained in the absence of nanoparticles and ODtreated was obtained in the presence of nanoparticles.
Preparation of docetaxel-loaded nanoparticles
A stock solution of docetaxel (5 mg/mL) was prepared and 200 µL was added to 20 mg of glutaraldehyde and UV + glucose cross-linked albumin nanoparticles. The volume was adjusted with water to 5.0 mL. The mixture was stirred for 4 h (650 rpm) at room temperature to achieve a loading equilibrium of docetaxel.
HPLC analysis for docetaxel release
Dialysis technique was used to evaluate drug release from albumin nanoprticles. A dialysis tube (molecular weight cut-off: 8 kDa) containing prepared docetaxel-loaded nanoparticles (5 mL) was put in a medium consisting of 20 mL PBS (pH =7.4) containing 0.1% Tween 80 and stirred continuously on a shaker incubator for over 12 days at 37 °C. At selected time intervals, 15 mL of the medium was removed and the medium was replenished with freshly prepared PBS. The aliquots were then exposed to dichloromethane for liquid-liquid extraction of docetaxel. The extraction procedure was repeated three times and the extracted organic phase was evaporated and the remnants were dissolved in 200 μL acetonitrile and were subjected to HPLC analysis. Drug release data were expressed as the percentage of the cumulative amount of drug release.
HPLC analysis of docetaxel
A Cecil 4200 HPLC system (Cecil instrument Ltd., UK) with UV–Visible detector was used for the quantification of docetaxel in the samples. Mobile phase was an isocratic mixture of water and acetonitrile (70:30) containing 0.1% trifluoroacetic acid and separation was obtained using a reverse phase column. The flow rate was set to 0.8 mL/min and absorption at 230 nm was recorded. The retention time was about 11 min. The levels of docetaxel in the samples were determined from calibration curve.
Long-time stability of docetaxel-loaded nanoparticles
Aqueous dispersions of docetaxel-loaded albumin nanoparticles were stored at 4 ºC for a period of 18 months. After pre-determined storage times, the samples were re-dispersed by vortexing for 1 min. As stability parameter, particle size and polydispersity were determined as described above.
Statistical analysis
All the quantitative results were expressed as mean ± standard error of the mean (SEM). Statistical analysis was carried out by means of one-way analysis of variance (ANOVA) followed by the Tukey post-test. p-value less than 0.05 were considered statistically significant.